Real world experience in the era of first generation protease inhibitors in the treatment of hepatitis C

被引：0

作者：

Hubbard H. ^{[1
]}

Lawitz E. ^{[2
]}

机构：

[1] Division of Gastroenterology, University of Texas Health Science Center San Antonio, Mail Code 7878, San Antonio, TX 78229

[2] Texas Liver Institute, University of Texas Health Science Center San Antonio, San Antonio, TX 78215

来源：

Current Hepatitis Reports | 2013年 / 12卷 / 4期

关键词：

Acting; Antivirals; Boceprevir; Direct; Experience; Hepatitis c; Inhibitors; Protease; Real; Telaprevir; Treatment; World;

D O I：

10.1007/s11901-013-0189-z

中图分类号：

学科分类号：

摘要：

The treatment for hepatitis C has been revolutionized with the new era of protease inhibitors. Boceprevir (BOC) and telaprevir (TVR) are potent first generation direct acting antivirals which have demonstrated significantly improved response rates compared to interferon and ribavirin in phase III trials. However there are multiple real-life data sets showing increased adverse events and treatment discontinuations compared to clinical trials, especially in the cirrhotic patient. The advent of all oral, non-interferon regimens offers a promising treatment paradigm for hepatitis C infected patients. © 2013 Springer Science+Business Media New York.

引用

页码：189 / 194

页数：5

共 35 条

[31]

Lawitz E., Mangia A., Wyles D., Et al., Sofosbuvir for previously untreated hepatitis C infection, N Engl J Med, 368, pp. 1878-1887, (2013)

[32]

Jacobson I.M., Gordon S.C., Kowdley K.V., Et al., Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options, N Engl J Med, 368, pp. 1867-1877, (2013)

[33]

Gane E.J., Stedman C.A., Hyland R.H., Et al., All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: The electron study, J Hepatol, 58, SUPPL., (2013)

[34]

Sulkowski M.S., Gardnier D.F., Rodriguez-Torres M., Et al., Sustained virologic response with daclatasvir plus sofosbuvir +/- ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC), J Hepatol, 58, SUPPL., (2013)

[35]

Soriano V., Gane E.J., Angus P.W., Et al., Efficacy and safety of the interferon (IFN)-free combination of B 201335 + BI 207127 +/- ribavirin (RBV) in treatment-naïve patients with HCV genotype (GT) 1 infection and compensated liver cirrhosis: Results from the SOUND-C2 study, Hepatology, 56, SUPPL., (2012)

← 1 2 3 4 →